Neo Candimyk (Itraconazole)

Itraconazole, the active ingredient in Neo Candimyk, is a triazole antifungal presented as an oral formulation for systemic use. It is prescribed to treat a range of fungal infections in adults and, when appropriate, pediatric patients under medical supervision.

GNH USA supplies Neo Candimyk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product conforms to European Union quality standards and our supply chain ensures timely delivery and regulatory compliance for each order.

Itraconazole is a triazole antifungal used to treat infections caused by dermatophytes, yeasts and moulds. - Dermatophyte infections: clears skin and nail infections caused by dermatophyte fungi. - Onychomycosis: improves nail appearance and eradicates fungal growth in infected toenails or fingernails. - Systemic candidiasis: eliminates invasive Candida species from bloodstream and internal organs. - Aspergillosis: controls invasive disease caused by Aspergillus species in immunocompromised patients. - Blastomycosis: treats infection caused by Blastomyces dermatitidis affecting lungs and skin. - Histoplasmosis: resolves systemic infection due to Histoplasma capsulatum.

Itraconazole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Headache: transient cranial discomfort. - Diarrhea: loose stools, usually self‑limiting. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: worsening of congestive heart failure, especially in patients with pre‑existing disease. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

Before prescribing Itraconazole, clinicians should consider several safety and handling precautions. - Liver function: monitor hepatic enzymes before and during therapy. - Cardiac status: avoid in patients with existing heart failure. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk. - Breastfeeding: not recommended while nursing. - Store at below 25°C: keep in original container, protect from moisture and light.

Itraconazole interacts with several medicines through enzyme inhibition or additive effects.

Major Interactions (Avoid): - Simvastatin: risk of severe myopathy; avoid co‑administration. - Midazolam: increased sedation; contraindicated. - Cisapride: potential cardiac arrhythmias; avoid.

Moderate Interactions (Monitor Closely): - Rifampin: reduces itraconazole levels, may diminish efficacy. - Ketoconazole: additive hepatotoxicity; monitor liver function. - Calcium channel blockers (e.g., verapamil): may increase itraconazole concentrations; adjust dose if needed.